22
Apr
Eli Lilly and Avidity Biosciences announce licensing & research cooperation
on combined monoclonal antibodies and oligonucleotide-based therapies for potential new medicines in immunology and other select indications. Read more here:
MORE →You are currently viewing a placeholder content from Mailchimp. To access the actual content, click the button below. Please note that doing so will share data with third-party providers.
More InformationYou need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information